OCLN and Atrophy: Ligustilide treatment reduced DSS-triggered weight loss, increased DAI scores, reduced spleen enlargement and thymic atrophy, increased colon length, restored colonic pathological structure, increased expressions of ZO-1 and Occludin, and decreased EGR1 downstream target protein ADAM17 expression.